(Q34568566)

3 August 2017

1 reference

title

Managing dyslipidemia in the high-risk patient (English)

1 reference

3 August 2017

1 reference

1 reference

Evan A Stein

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

American Journal of Cardiology

3 August 2017

published in

1 reference

3 August 2017

volume

89

1 reference

3 August 2017

issue

5A

1 reference

3 August 2017

page(s)

50C-57C

1 reference

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Statins: effective antiatherosclerotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Prospective evaluation of a stiff shaft glide wire compared with the standard straight wire in crossing severely stenotic aortic valves

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Assoc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Intestinal bile salt transport: structure-activity relationships and other properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

Multiple contributors to coronary risk implications for screening and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902229-4

10.1016/S0002-9149(02)02229-4

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference